{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:29:23Z","timestamp":1785446963801,"version":"3.56.0"},"reference-count":39,"publisher":"Bioscientifica","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["eor.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Considering the adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids for treating osteoarthritis (OA), development of drugs that are more effective and better tolerated than existing treatments is urgently needed. This systematic review aimed to evaluate the efficacy and safety of anti-nerve growth factor (NGF) monoclonal antibodies vs active comparator therapy, such as NSAIDs and oxycodone, in treating hip or knee OA.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Databases were comprehensively searched for randomized controlled trials (RCTs) published before January 2022. Efficacy and safety outcomes were assessed.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Six RCTs that included 4325 patients were identified. Almost all the RCTs indicated that moderate doses of anti-NGF monoclonal antibody treatment significantly improved efficacy outcomes based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score, the WOMAC physical function score and the Patient\u2019s Global Assessment compared with those of the active comparator. At least half of the RCTs indicated that the incidence of severe adverse events, withdrawals due to adverse events (AEs) and total joint replacement were not significantly different between anti-NGF monoclonal antibody treatment and active comparator therapy, but the outcomes of some studies may have been limited by a short duration of follow-up. Most RCTs suggested that anti-NGF monoclonal antibody treatment had a lower incidence of gastrointestinal and cardiovascular AEs. However, the majority of RCTs reported a higher incidence of abnormal peripheral sensation with anti-NGF monoclonal antibody treatment. Furthermore, the higher incidence of rapidly progressive osteoarthritis (RPOA) with anti-NGF monoclonal antibody treatment should also not be overlooked, and the identification of patient characteristics that increase the risk of RPOA is critical in further studies.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Based on the current research evidence, anti-NGF monoclonal antibodies are not yet a replacement for analgesic drugs such as NSAIDs but might be a new treatment option for hip or knee OA patients who are intolerant or unresponsive to nonopioid or opioid treatment. Notably, however, considering the inconsistency and inconclusive evidence on the safety outcomes of recent studies, more research is needed, and long-term follow-up is required.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>","DOI":"10.1530\/eor-21-0103","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T09:19:58Z","timestamp":1657012798000},"page":"470-480","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":7,"title":["Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials"],"prefix":"10.1530","volume":"7","author":[{"given":"Di","family":"Zhao","sequence":"first","affiliation":[{"name":"The Second Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China"},{"name":"Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-feng","family":"Zeng","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China"},{"name":"Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-hong","family":"Liang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China"},{"name":"Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ke","family":"Pan","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-hui","family":"Luo","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-hong","family":"Han","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2440-4064","authenticated-orcid":true,"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China"},{"name":"Guangdong Second Traditional Chinese Medicine Hospital (Guangdong Province Engineering Technology Research Institute of Traditional Chinese Medicine), Guangzhou, China"},{"name":"The fifth Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-yi","family":"Yang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"issue":"Supplement 120","key":"bib1","series-title":"Clinical and Experimental Rheumatology","first-page":"31","article-title":"Public health interventions for osteoarthritis \u2013 updates on the Osteoarthritis Action Alliance\u2019s efforts to address the 2010 OA public health agenda recommendations","volume":"37","author":"Callahan","year":"2019","unstructured":"Callahan LFAmbrose KRAlbright ALAltpeter MGolightly YMHuffman KFNelson AEWeisner SE. Public health interventions for osteoarthritis \u2013 updates on the Osteoarthritis Action Alliance\u2019s efforts to address the 2010 OA public health agenda recommendations. Clinical and Experimental Rheumatology201937 (Supplement 120) 31\u201339."},{"issue":"Supplement 120","key":"bib2","series-title":"Clinical and Experimental Rheumatology","first-page":"3","article-title":"Osteoarthritis is a serious disease","volume":"37","author":"Hawker","year":"2019","unstructured":"Hawker GAOsteoarthritis is a serious disease. Clinical and Experimental Rheumatology201937 (Supplement 120) 3\u20136."},{"key":"bib3","series-title":"Arthritis and Rheumatism","first-page":"378","article-title":"Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia","volume":"43","author":"Wolfe","year":"2000","unstructured":"Wolfe FZhao SLane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis and Rheumatism200043378\u2013385. (https:\/\/doi.org\/10.1002\/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2)"},{"issue":"8Supplement","key":"bib4","series-title":"American Journal of Managed Care","first-page":"S236","article-title":"Practical considerations for the pharmacologic management of osteoarthritis","volume":"15","author":"Altman","year":"2009","unstructured":"Altman RDPractical considerations for the pharmacologic management of osteoarthritis. American Journal of Managed Care200915 (8Supplement) S236\u2013S243."},{"key":"bib5","series-title":"Anesthesiology","first-page":"189","article-title":"Antagonism of nerve growth factor-TrkA signaling and the relief of pain","volume":"115","author":"Mantyh","year":"2011","unstructured":"Mantyh PWKoltzenburg MMendell LMTive LShelton DL. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology2011115189\u2013204. (https:\/\/doi.org\/10.1097\/ALN.0b013e31821b1ac5)"},{"key":"bib6","series-title":"Drugs","first-page":"619","article-title":"Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?","volume":"74","author":"Bannwarth","year":"2014","unstructured":"Bannwarth BKostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?Drugs201474619\u2013626. (https:\/\/doi.org\/10.1007\/s40265-014-0208-6)"},{"key":"bib7","series-title":"BMJ","article-title":"Neuropathic pain: mechanisms and their clinical implications","volume":"348","author":"Cohen","year":"2014","unstructured":"Cohen SPMao J. Neuropathic pain: mechanisms and their clinical implications. BMJ2014348 f7656. (https:\/\/doi.org\/10.1136\/bmj.f7656)"},{"key":"bib8","series-title":"Journal of Neuroscience","first-page":"8593","article-title":"Persistent nociception triggered by nerve growth factor (NGF) is mediated by TRPV1 and oxidative mechanisms","volume":"35","author":"Eskander","year":"2015","unstructured":"Eskander MARuparel SGreen DPChen PBPor EDJeske NAGao XFlores ERHargreaves KM. Persistent nociception triggered by nerve growth factor (NGF) is mediated by TRPV1 and oxidative mechanisms. Journal of Neuroscience2015358593\u20138603. (https:\/\/doi.org\/10.1523\/JNEUROSCI.3993-14.2015)"},{"key":"bib9","series-title":"Trends in Pharmacological Sciences","first-page":"85","article-title":"Novel class of pain drugs based on antagonism of NGF","volume":"27","author":"Hefti","year":"2006","unstructured":"Hefti FFRosenthal AWalicke PAWyatt SVergara GShelton DLDavies AM. Novel class of pain drugs based on antagonism of NGF. Trends in Pharmacological Sciences20062785\u201391. (https:\/\/doi.org\/10.1016\/j.tips.2005.12.001)"},{"key":"bib10","series-title":"Arthritis and Rheumatism","first-page":"181","article-title":"The relationship of vibratory perception to dynamic joint loading, radiographic severity, and pain in knee osteoarthritis","volume":"64","author":"Shakoor","year":"2012","unstructured":"Shakoor NLee KJFogg LFWimmer MAFoucher KCMikolaitis RABlock JA. The relationship of vibratory perception to dynamic joint loading, radiographic severity, and pain in knee osteoarthritis. Arthritis and Rheumatism201264181\u2013186. (https:\/\/doi.org\/10.1002\/art.30657)"},{"key":"bib11","series-title":"Arthritis and Rheumatology","first-page":"382","article-title":"When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program","volume":"68","author":"Hochberg","year":"2016","unstructured":"Hochberg MCTive LAAbramson SBVignon EVerburg KMWest CRSmith MDHungerford DS. When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis and Rheumatology201668382\u2013391. (https:\/\/doi.org\/10.1002\/art.39492)"},{"issue":"Supplement 1","key":"bib12","series-title":"Osteoarthritis and Cartilage","first-page":"S18","article-title":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","volume":"23","author":"Hochberg","year":"2015","unstructured":"Hochberg MCSerious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis and Cartilage201523 (Supplement 1) S18\u2013S21. (https:\/\/doi.org\/10.1016\/j.joca.2014.10.005)"},{"key":"bib13","series-title":"BMJ","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","unstructured":"Liberati AAltman DGTetzlaff JMulrow CG\u00f8tzsche PCIoannidis JPClarke MDevereaux PJKleijnen JMoher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ2009339 b2700. (https:\/\/doi.org\/10.1136\/bmj.b2700)"},{"key":"bib14","series-title":"PLoS Medicine","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","unstructured":"Liberati AAltman DGTetzlaff JMulrow CGotzsche PCIoannidis JPClarke MDevereaux PJKleijnen JMoher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine20096 e1000100. (https:\/\/doi.org\/10.1371\/journal.pmed.1000100)"},{"key":"bib15","series-title":"BMJ","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","unstructured":"Higgins JPAltman DGGotzsche PCJ\u00fcni PMoher DOxman ADSavovic JSchulz KFWeeks LSterne JA, et al.The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ2011343 d5928. (https:\/\/doi.org\/10.1136\/bmj.d5928)"},{"key":"bib16","series-title":"Journal of Rheumatology","first-page":"2249","article-title":"Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen","volume":"41","author":"Ekman","year":"2014","unstructured":"Ekman EFGimbel JSBello AESmith MDKeller DSAnnis KMBrown MTWest CRVerburg KM. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. Journal of Rheumatology2014412249\u20132259. (https:\/\/doi.org\/10.3899\/jrheum.131294)"},{"key":"bib17","series-title":"International Journal of Clinical Practice","first-page":"493","article-title":"Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial","volume":"70","author":"Mayorga","year":"2016","unstructured":"Mayorga AJWang SKelly KMThipphawong J. Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. International Journal of Clinical Practice201670493\u2013505. (https:\/\/doi.org\/10.1111\/ijcp.12807)"},{"key":"bib18","series-title":"Arthritis and Rheumatology","first-page":"1167","article-title":"Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial","volume":"73","author":"Hochberg","year":"2021","unstructured":"Hochberg MCCarrino JASchnitzer TJGuermazi AWalsh DAWhite ANakajo SFountaine RJHickman APixton G, et al.Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial. Arthritis and Rheumatology2021731167\u20131177. (https:\/\/doi.org\/10.1002\/art.41674)"},{"key":"bib19","series-title":"Annals of the Rheumatic Diseases","first-page":"1202","article-title":"Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain","volume":"74","author":"Schnitzer","year":"2015","unstructured":"Schnitzer TJEkman EFSpierings ELGreenberg HSSmith MDBrown MTWest CRVerburg KM. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Annals of the Rheumatic Diseases2015741202\u20131211. (https:\/\/doi.org\/10.1136\/annrheumdis-2013-204905)"},{"key":"bib20","series-title":"Pain","first-page":"1603","article-title":"A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee","volume":"154","author":"Spierings","year":"2013","unstructured":"Spierings ELHFidelholtz JWolfram GSmith MDBrown MTWest CR. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain20131541603\u20131612. (https:\/\/doi.org\/10.1016\/j.pain.2013.04.035)"},{"key":"bib21","series-title":"Pain Medicine","first-page":"585","article-title":"Safety of low-dose tanezumab in the treatment of hip or knee osteoarthritis: a systemic review and meta-analysis of randomized phase III clinical trials","volume":"22","author":"Yu","year":"2021","unstructured":"Yu YLu STSun JPZhou W. Safety of low-dose tanezumab in the treatment of hip or knee osteoarthritis: a systemic review and meta-analysis of randomized phase III clinical trials. Pain Medicine202122585\u2013595. (https:\/\/doi.org\/10.1093\/pm\/pnaa260)"},{"key":"bib22","series-title":"Nature Reviews: Drug Discovery","first-page":"337","article-title":"Anti-NGF painkillers back on track?","volume":"11","author":"Holmes","year":"2012","unstructured":"Holmes DAnti-NGF painkillers back on track?Nature Reviews: Drug Discovery201211337\u2013338. (https:\/\/doi.org\/10.1038\/nrd3732)"},{"key":"bib23","series-title":"Seminars in Arthritis and Rheumatism","first-page":"109","article-title":"Nerve growth factor in rheumatic diseases","volume":"40","author":"Seidel","year":"2010","unstructured":"Seidel MFHerguijuela MForkert ROtten U. Nerve growth factor in rheumatic diseases. Seminars in Arthritis and Rheumatism201040109\u2013126. (https:\/\/doi.org\/10.1016\/j.semarthrit.2009.03.002)"},{"key":"bib24","series-title":"Drugs","first-page":"1377","article-title":"Nerve growth factor antagonists: is the future of monoclonal antibodies becoming clearer?","volume":"77","author":"Bannwarth","year":"2017","unstructured":"Bannwarth BKostine M. Nerve growth factor antagonists: is the future of monoclonal antibodies becoming clearer?Drugs2017771377\u20131387. (https:\/\/doi.org\/10.1007\/s40265-017-0781-6)"},{"key":"bib25","series-title":"Nature Reviews: Rheumatology","first-page":"34","article-title":"The evolution of nerve growth factor inhibition in clinical medicine","volume":"17","author":"Wise","year":"2021","unstructured":"Wise BLSeidel MFLane NE. The evolution of nerve growth factor inhibition in clinical medicine. Nature Reviews: Rheumatology20211734\u201346. (https:\/\/doi.org\/10.1038\/s41584-020-00528-4)"},{"key":"bib26","series-title":"Osteoarthritis and Cartilage","first-page":"484","article-title":"Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients","volume":"27","author":"Karsdal","year":"2019","unstructured":"Karsdal MAVerburg KMWest CRBay-Jensen ACKeller DSArends RHGP. Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients. Osteoarthritis and Cartilage201927484\u2013492. (https:\/\/doi.org\/10.1016\/j.joca.2018.12.001)"},{"key":"bib27","series-title":"JAMA","first-page":"37","article-title":"Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial","volume":"322","author":"Schnitzer","year":"2019","unstructured":"Schnitzer TJEaston RPang SLevinson DJPixton GViktrup LDavignon IBrown MTWest CRVerburg KM. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA201932237\u201348. (https:\/\/doi.org\/10.1001\/jama.2019.8044)"},{"key":"bib28","series-title":"Osteoarthritis and Cartilage","first-page":"776","article-title":"Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration","volume":"24","author":"Losina","year":"2016","unstructured":"Losina EMichl GCollins JEHunter DJJordan JMYelin EPaltiel ADKatz JN. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. Osteoarthritis and Cartilage201624776\u2013785. (https:\/\/doi.org\/10.1016\/j.joca.2015.12.011)"},{"issue":"Supplement_4","key":"bib29","series-title":"Rheumatology","first-page":"v99","article-title":"What is new in pain modification in osteoarthritis?","volume":"57","author":"Miller","year":"2018","unstructured":"Miller REBlock JAMalfait AM. What is new in pain modification in osteoarthritis?Rheumatology201857 (Supplement_4) v99\u2013v107. (https:\/\/doi.org\/10.1093\/rheumatology\/kex522)"},{"key":"bib30","series-title":"New England Journal of Medicine","first-page":"1521","article-title":"Tanezumab for the treatment of pain from osteoarthritis of the knee","volume":"363","author":"Lane","year":"2010","unstructured":"Lane NESchnitzer TJBirbara CAMokhtarani MShelton DLSmith MDBrown MT. Tanezumab for the treatment of pain from osteoarthritis of the knee. New England Journal of Medicine20103631521\u20131531. (https:\/\/doi.org\/10.1056\/NEJMoa0901510)"},{"key":"bib31","series-title":"Clinical Therapeutics","first-page":"1435","article-title":"Efficacy, safety, and tolerability of fulranumab as an adjunctive therapy in patients with inadequately controlled, moderate-to-severe chronic low back pain: a randomized, double-blind, placebo-controlled, dose-ranging, dose-loading phase II study","volume":"38","author":"Sanga","year":"2016","unstructured":"Sanga PPolverejan EWang SKelly KMThipphawong J. Efficacy, safety, and tolerability of fulranumab as an adjunctive therapy in patients with inadequately controlled, moderate-to-severe chronic low back pain: a randomized, double-blind, placebo-controlled, dose-ranging, dose-loading phase II study. Clinical Therapeutics2016381435\u20131450. (https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.030)"},{"key":"bib32","series-title":"Pain","first-page":"1009","article-title":"Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain","volume":"154","author":"Kivitz","year":"2013","unstructured":"Kivitz AJGimbel JSBramson CNemeth MAKeller DSBrown MTWest CRVerburg KM. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain20131541009\u20131021. (https:\/\/doi.org\/10.1016\/j.pain.2013.03.006)"},{"key":"bib33","series-title":"Pain","first-page":"2248","article-title":"Efficacy and safety of tanezumab in the treatment of chronic low back pain","volume":"152","author":"Katz","year":"2011","unstructured":"Katz NBorenstein DGBirbara CBramson CNemeth MASmith MDBrown MT. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain20111522248\u20132258. (https:\/\/doi.org\/10.1016\/j.pain.2011.05.003)"},{"key":"bib34","series-title":"Journal of Pain","first-page":"790","article-title":"Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial","volume":"13","author":"Brown","year":"2012","unstructured":"Brown MTMurphy FTRadin DMDavignon ISmith MDWest CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. Journal of Pain201213790\u2013798. (https:\/\/doi.org\/10.1016\/j.jpain.2012.05.006)"},{"key":"bib35","series-title":"Arthritis and Rheumatism","first-page":"1795","article-title":"Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial","volume":"65","author":"Brown","year":"2013","unstructured":"Brown MTMurphy FTRadin DMDavignon ISmith MDWest CR. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis and Rheumatism2013651795\u20131803. (https:\/\/doi.org\/10.1002\/art.37950)"},{"key":"bib36","series-title":"Annals of the Rheumatic Diseases","first-page":"1665","article-title":"Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial","volume":"73","author":"Balanescu","year":"2014","unstructured":"Balanescu ARFeist EWolfram GDavignon ISmith MDBrown MTWest CR. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Annals of the Rheumatic Diseases2014731665\u20131672. (https:\/\/doi.org\/10.1136\/annrheumdis-2012-203164)"},{"key":"bib37","series-title":"American Journal of Therapeutics","first-page":"63","article-title":"Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics","volume":"7","author":"Whelton","year":"2000","unstructured":"Whelton ARenal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. American Journal of Therapeutics2000763\u201374. (https:\/\/doi.org\/10.1097\/00045391-200007020-00004)"},{"issue":"Supplement 1","key":"bib38","series-title":"American Journal of Medicine","first-page":"S3","article-title":"Opioids for chronic pain: new evidence, new strategies, safe prescribing","volume":"126","author":"de Leon-Casasola","year":"2013","unstructured":"de Leon-Casasola OAOpioids for chronic pain: new evidence, new strategies, safe prescribing. American Journal of Medicine2013126 (Supplement 1) S3\u2013S11. (https:\/\/doi.org\/10.1016\/j.amjmed.2012.11.011)"},{"issue":"Supplement 1","key":"bib39","series-title":"Clinical Drug Investigation","first-page":"53","article-title":"Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain","volume":"32","author":"Labianca","year":"2012","unstructured":"Labianca RSarzi-Puttini PZuccaro SMCherubino PVellucci RFornasari D. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. Clinical Drug Investigation201232 (Supplement 1) 53\u201363. (https:\/\/doi.org\/10.2165\/11630080-000000000-00000)"}],"container-title":["EFORT Open Reviews"],"original-title":[],"link":[{"URL":"https:\/\/eor.bioscientifica.com\/view\/journals\/eor\/7\/7\/EOR-21-0103.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eor.bioscientifica.com\/downloadpdf\/journals\/eor\/7\/7\/EOR-21-0103.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/eor.bioscientifica.com\/downloadpdf\/journals\/eor\/7\/7\/EOR-21-0103.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:50:38Z","timestamp":1784555438000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/eor\/article\/7\/7\/470-480\/2476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":39,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.1530\/eor-21-0103","relation":{},"ISSN":["2058-5241"],"issn-type":[{"value":"2058-5241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}